BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37772547)

  • 1. Immune Cell Infiltration and Clinical Significance of Angiogenesis-related Genes in Lung Adenocarcinoma.
    Zhao QI; Ren W; Gao S; Mu N
    Anticancer Res; 2023 Oct; 43(10):4473-4489. PubMed ID: 37772547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
    Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
    Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
    Yang Q; Zhu W; Gong H
    Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
    Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis.
    Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L
    Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an invasion score based on metastasis-related pathway activity profiles for identifying invasive molecular subtypes of lung adenocarcinoma.
    Han T; Liu Y; Zhou J; Guo J; Xing Y; Xie J; Bai Y; Wu J; Hu D
    Sci Rep; 2024 Jan; 14(1):1692. PubMed ID: 38243040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma.
    Dong Y; Yu X; Song H; Chen Q; Zheng B; Ji X; Xu M; Liu J; Sun X; Wang Q; Ren R; Lu H
    Cell Cycle; 2023; 22(23-24):2566-2583. PubMed ID: 38164943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients.
    Guo Q; Li K; Jiang N; Zhou R; Rao XR; Wu CY
    Aging (Albany NY); 2023 Sep; 15(18):9633-9660. PubMed ID: 37737707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma.
    Wei S; Xing J; Lu K; Wang K; Yu W
    Hereditas; 2023 May; 160(1):27. PubMed ID: 37254219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
    Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
    Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.
    Zhang H; Lin J; Yahaya BH
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):44. PubMed ID: 38281298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
    Li Q; Tang Y; Wang T; Zhu J; Zhou Y; Shi J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):307-323. PubMed ID: 36575346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of radiotherapy-related autophagy genes in the prognosis and immune infiltration in lung adenocarcinoma.
    Gao J; Lu F; Yan J; Wang R; Xia Y; Wang L; Li L; Chang L; Li W
    Front Immunol; 2022; 13():992626. PubMed ID: 36311724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.